Contact this trialFirst, we need to learn more about you.
Complement Inhibitor
Iptacopan for Complement 3 Glomerulopathy
Recruiting1 awardPhase 3
New York, New York
This trial will study whether a new drug, iptacopan, is effective and safe for treating complement 3 glomerulopathy, a kidney disease. The trial will be conducted at multiple centers, with patients randomly assigned to receive either the drug or a placebo. The trial will be double-blind, meaning neither the patients nor the study staff will know who is receiving the drug or the placebo.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.